2017 Press Releases

August 15, 2017
American Diabetes Association Deeply Concerned with Recent Prescription Drug Formulary Trends
The Association is deeply concerned with recent trends in prescription drug formulary designs that result in frequent changes in drug coverage for individuals with diabetes. As pharmacy benefits managers (PBMs), insurers and employers finalize their 2018 formulary lists, the Association urges them to focus on continuity of care for individuals with diabetes.

July 28, 2017
American Diabetes Association® and American Association of Diabetes Educators Issue 2017 National Standards for Diabetes Self-Management Education and Support
The American Diabetes Association (Association) and the American Association of Diabetes Educators (AADE) are publishing the “2017 National Standards for Diabetes Self-Management Education and Support” (Standards). The detailed recommendations, which are updated regularly, will be published online on July 28, 2017, and in the September 2017 issues of Diabetes Care and The Diabetes Educator.

July 24, 2017
12 National Patient Advocacy Organizations Urge Senate to Vote “No” on Advancing ACA Repeal and to Safeguard the Health and Lives of Millions of Americans with a Bipartisan Approach to Reform
12 nonpartisan, patient and provider groups representing millions of Americans issued the following statement today ahead of the Senate procedural vote to advance repeal of the Patient Protection and Affordable Care Act (ACA).

July 18, 2017
15 national patient advocacy organizations urge Congress to oppose the ACA repeal and take a bipartisan approach to reform
15 nonpartisan patient and provider groups representing millions of Americans issued the following statement today on the Senate’s proposal to repeal the Affordable Care Act (ACA).

July 18, 2017
American Diabetes Association Concurs with CDC’s Call for Continued Urgency to Decrease the Burden of Diabetes
The American Diabetes Association urges renewed attention to and investment in stemming the diabetes epidemic, following the release of the Centers for Disease Control and Prevention’s (CDC) National Diabetes Statistics Report, 2017. The new report reviewed 2015 data to confirm more than 114 million Americans have diabetes or prediabetes.

July 14, 2017
Mental Health Provider Diabetes Education Program, a Joint Initiative of the American Diabetes Association and the American Psychological Association, Receives Nearly $1 Million Grant from the Helmsley Charitable Trust
In collaboration with the American Psychological Association, the American Diabetes Association’s first Mental Health Provider Diabetes Education Program, which was launched last month, has received an $839,000 grant from The Leona M. and Harry B. Helmsley Charitable Trust to support the program.

June 23, 2017
American Diabetes Association Urges Senators to Vote Against Proposed Health Care Legislation
The American Diabetes Association has grave concerns about the impact the draft Senate health care bill will have on people with diabetes. Individuals with diabetes need access to continuous health care to effectively manage their disease and to prevent dangerous and costly complications.

June 13, 2017
Daily, Long-Acting Oral Insulin Tablet Provides Comparable Glycemic Control to Insulin Glargine Injection in Patients with Type 2 Diabetes
A long-acting, oral insulin tablet has been found to safely improve glycemic control as effectively as the common, injected insulin glargine in people with Type 2 diabetes, according to the study, “Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM).”

June 13, 2017
Glucagon-Blocking Drug Reduces Need for Insulin and Improves Blood Glucose Levels for Patients with Type 1 Diabetes
A single dose of the glucagon-blocking drug REMD-477 can substantially reduce the amount of insulin needed and improve glucose levels without increasing hypoglycemia (low blood glucose levels) in patients with type 1 diabetes, according to the study, “REMD-477, a Human Glucagon Receptor (GCGR) Antibody, Reduces Daily Insulin Requirements and Improves Glycemic Control in People with Type 1 Diabetes (T1D).”

June 13, 2017
SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes
A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for heart failure when used to treat patients with type 2 diabetes, both with or without existing cardiovascular disease, and regardless of the specific SGLT2 inhibitor used, according to a study, “Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD-REAL Study.”

June 13, 2017
Increased Risk of Depression, Anxiety and Disordered Eating for People with Diabetes—Psychosocial Care is Key
Details of a new initiative focused on educating mental health providers on psychosocial care of people with diabetes and the results of two research studies focused on various psychosocial aspects of living with diabetes were highlighted at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 12, 2017
Autoantigen GAD-Vaccine is Safe for Children at High Risk for Developing Type 1 Diabetes
Treatment with autoantigen specific therapies, such as Alum-GAD, is safe to give to children with an increased risk for developing type 1 diabetes, however, it does not prevent the development of the disease, investigators explained in the research study, “A Double-Blind, Randomized Investigator-initiated Study to Determine the Safety and the Effect of Diamyd® on the Progression to Type 1 Diabetes in Children With Multiple Islet Cell Autoantibodies.”

June 12, 2017
Health Disparities Among Patients with Diabetes Can Be Improved by New Approaches and Insights
Health disparities in the U.S., including inequalities in the delivery of care and access to care across various racial, ethnic and socioeconomic groups, are of widespread concern, particularly in people with diabetes who require continuous, regular health care to effectively manage their disease.

June 12, 2017
Hybrid Closed-Loop System Demonstrates Effectiveness in Controlling Glucose Levels in Children and Adults with Type 1 Diabetes
The performance of closed-loop systems and their ability to prevent hypoglycemia is highlighted in two studies presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 12, 2017
New, Long-Acting Insulin Therapy Demonstrates Cardiovascular Safety and Reduces the Risk of Severe Hypoglycemia
A new, ultra-long acting insulin product, insulin degludec, has comparable cardiovascular safety to insulin glargine U100 and is also associated with significant reductions in severe hypoglycemia, investigators presented during a symposium today, titled “Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results,” at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 12, 2017
Structured Care Program Offers Youth with Type 1 Diabetes Improved Transition from Pediatric to Adult Care
Adolescents and young adults with type 1 diabetes benefit from a structured transition program when changing from pediatric to adult diabetes care, resulting in improvements in clinic attendance and satisfaction, as well as decreased emotional burden for the duration of intervention, according to the study, “A Structured Transition Program in Young Adults with Type 1 Diabetes Is Associated with Improved Satisfaction with Diabetes Care,” presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 11, 2017
Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
The medication alirocumab, a PCSK9 inhibitor, reduces LDL cholesterol levels as well as non-high-density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes, according to two ODYSSEY DIABETES (DM) presentations at the “Inhibition of PCSK9 in Dyslipidemia Patients with Diabetes” symposium at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 11, 2017
Long-Term Metformin Treatment Found to Reduce Risk of Heart Disease in Adults with Type 1 Diabetes
Metformin may be an effective long-term strategy worthy of adding to an individual’s diabetes care plan in order to reduce the risk of heart disease in adults with type 1 diabetes, according to the findings of the study titled, “Results of the JDRF Reducing with Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL),” presented at the American Diabetes Association’s 77th Scientific Sessions® at the San Diego Convention Center.

June 10, 2017
A Two-Way Text Messaging System Benefits Glycemic Control for Teens with Type 1 Diabetes
Teens with type 1 diabetes (T1D) who adhere to frequent communication through a two-way text messaging system were found to maintain or improve A1C levels while preparing to transition from pediatric to adult care settings, according to the study, “Text Message Intervention for Teens with Type 1 Diabetes (T1D) Preserves A1C: Results of an RCT.”

June 9, 2017
Severe Obesity in High-Risk Youth Correlates Directly to Increased Incidence of Type 2 Diabetes
The risk of developing type 2 diabetes (T2D) by age 20 was 12 times as high in severely obese American Indian children 5 to 9 years of age as in normal-weight youth in that age range, according to a study titled “Long-term Risk of Type 2 Diabetes in Youth with Increasing Severity of Obesity.”

Items 1 - 20 of 62  1234Next